Aptar Pharma has partnered with Shanghai Sine Promod Pharmaceutical to develop and launch its new budesonide dry powder inhaler (DPI), which features Aptar Pharma’s user-friendly and cost-effective Twister DPI.
Aptar Pharma has partnered with Shanghai Sine Promod Pharmaceutical to develop and launch its new budesonide dry powder inhaler (DPI), which features Aptar Pharma’s user-friendly and cost-effective Twister DPI. Budesonide, an inhaled corticosteroid for maintenance therapy in patients with asthma, is the first product marketed with Aptar Pharma’s Twister technology. The product is marketed in two forms, one containing 30 capsules and the other with 60 capsules. Each capsule consists of 200 mcg of budesonide blended with lactose monohydrate as the carrier.
Aptar Pharma developed Twister, which is a new capsule-based DPI, to address unmet medical needs in fast-growing asthma and COPD markets. The design of Twister is simple and robust, with few components to ensure cost-effective production. The technology has been tested and validated with a number of different dry powder drug formulations.
Twister has been designed to be patient-friendly and easy to use, allowing patients easy access to their medication in three simple steps: insert, twist, and inhale. The DPI is transparent, hence, allowing the capsule and powder to be seen in the device as they are administered, this feature was designed as a means to improve patient compliance by providing visual cues. In addition, the patient is also guided by audible feedback during inhalation.
Source: Aptar Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.